Tofacitinib – the fi rst JAK inhibitor in the treatment of ulcerative colitis. Beginning of the therapeutic era of „small molecules“ in infl ammatory bowel disease?

Česká verzia

Authors: Lukáš M.
Authors place of work: Klinické a výzkumné centrum pro střevní záněty ISCARE I. V. F. a. s. a 1. LF UK, Praha
Published in the journal: Gastroent Hepatol 2019; 73(4): 363-365
Category:
doi: https://doi.org/10.14735/amgh2019363

Zdroje

1. Vaníčková R, Lukáš M. „Malé molekuly“ v léčbě idiopatických střevních zánětů. Farmakoterapeutická revue 2018; 4.

2. Cramer JA, Roy A, Burrell A et al. Medication compliance and persistence: terminology and deﬁnitions. Value Heal 2008; 11 (1): 44–47. doi: 10.1111/j.1524-4733.2007.00213.x.

3. Šenolt L. Inhibice Janus kinázy v léčbě revmatoidní artritidy. Farmakoterapie 2011 (3): 283–289.

4. Sandborn WJ, Ghosh S, Panes J et al. Tofacitinib, an oral janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 2012; 367 (7): 616–624. doi: 10.1056/NEJMoa1112168.

5. Sandborn WJ, Su C, Sands BE et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2017; 376 (18): 1723–1736. doi: 10.1056/NEJMoa1606910.

6. Rubin DT, Dubinski M, Lukas M et al. Long-term efficacy of tofacitinib in patients who received extended induction therapy: results from OCTAVE open study for tofacitinib delayed responders. J Crohns Colitis 2019; 13 (Suppl 1): S050–S052. doi: 10.1093/ecco-jcc/jjy222.077.

7. European Medicines Agency. Restrictions in use of Xeljanz while EMA reviews risk of blood clots in lungs. 2019. [online]. Available from: https: //www.ema.europa.eu/en/news/restrictions-use-xeljanz-while-ema-reviews-risk-blood-clots-lungs.